Vaccine Research International Plc has carried out a successful Phase I Clinical Trial of vaccine SA75 against hospital-acquired infections caused by staphylococcal bacteria (which include drug-resistant strains for example MRSA). The Trial indicated that the vaccine is safe for humans and stimulates immune responses. VRi is now working towards further clinical trials to examine the potential of vaccine SA75 to prevent staphylococcal infections in hospital patients and the wider community.